Table 3

Diagnosis and management of standardised patients simulating peripheral SpA

Educational group (n=19)p Value (within group)Control group (n=40)p Value (within group)
Round 1 (%)Round 2 (%)Change score (%)Round 1 (%)Round 2 (%)Change score (%)p Value (change scores, between groups)
Number 1 diagnosis
 Peripheral SpA2 (11)5 (26)3 (16)0.454 (10)4 (10)0 (0)1.000.21
 Reactive arthritis2 (11)1 (5)−1 (−6)1.004 (10)3 (8)−1 (−2)1.000.79
 SpA0 (0)3 (16)3 (16)0.250 (0)0 (0)0 (0)NA0.01
 Psoriatic arthritis0 (0)1 (5)1 (5)1.000 (0)0 (0)0 (0)NA0.15
 Tenosynovitis0 (0)0 (0)0 (0)NA0 (0)1 (3)1 (3)1.000.49
 Arthritis, not otherwise specified5 (26)8 (42)3 (16)0.4515 (38)16 (40)1 (2)1.000.44
 Rheumatoid arthritis5 (26)3 (16)−2 (−10)0.692 (5)5 (13)3 (8)0.450.18
 Gout1 (5)1 (5)0 (0)1.008 (20)6 (15)−2 (−5)0.770.70
 Sprain4 (21)1 (5)−3 (−16)0.256 (15)5 (13)−1 (−2)1.000.30
 Skin or nail infection/insect bite2 (11)0 (0)−2 (−11)0.503 (8)1 (3)−2 (−5)0.250.70
 Trauma0 (0)1 (5)1 (5)1.001 (3)1 (3)0 (0)1.000.49
 Other or no differential diagnosis0 (0)1 (5)1 (5)1.001 (3)2 (5)1 (2)1.000.71
Additional diagnostic tests
 Laboratory tests (general)8 (42)5 (26)−3 (−16)0.3817 (43)18 (45)1 (3)1.000.18
 HLA-B27 test0 (0)0 (0)0 (0)NA0 (0)0 (0)0 (0)NA1.00
 IgM RF and/or ACPA test5 (26)2 (11)−3 (−16)0.3811 (28)7 (18)−4 (−10)0.290.64
 Radiograph of the hand or foot0 (0)1 (5)1 (5)1.004 (10)8 (20)4 (10)0.220.59
Management
 NSAIDs prescribed13 (68)13 (68)0 (0)1.0021 (53)22 (55)1 (3)1.000.86
 Arranged follow-up consultation with GP (resident)10 (53)10 (53)0 (0)1.0023 (58)25 (63)2 (5)0.820.82
  • Values are expressed as number (percentage) of participants. Numbers may not add up due to rounding. NcNemar tests were used within groups and Mann-Whitney U tests were used between groups.

  • ACPA, anticitrullinated protein antibody; GP, general practitioner; HLA-B27, human leukocyte antigen B27; NA, not assessed; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; SpA, spondyloarthritis; SPs, standardised patients.